TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Authors
Keywords
-
Journal
JOURNAL OF NANOBIOTECHNOLOGY
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-06
DOI
10.1186/s12951-023-02183-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
- (2023) Pasquale Lombardi et al. Cancers
- Targeting Trop-2 in cancer: Recent research progress and clinical application
- (2023) Shuying Qiu et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)
- (2023) Claudia Parisi et al. CANCER TREATMENT REVIEWS
- Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG
- (2022) Chihiro Ishiwatari-Ogata et al. Frontiers in Immunology
- TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer
- (2022) Michela Cortesi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer
- (2022) Xinlin Liu et al. PHARMACOLOGY & THERAPEUTICS
- PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
- (2022) Xiaolu Yu et al. Journal for ImmunoTherapy of Cancer
- Nucleic acid nanoassembly-enhanced RNA therapeutics and diagnosis
- (2022) Mengnan Zhao et al. Acta Pharmaceutica Sinica B
- Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
- (2022) Mythili Shastry et al. BREAST
- Ozoralizumab: First Approval
- (2022) Susan J. Keam DRUGS
- Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132
- (2022) Yezhe Cheng et al. Frontiers in Oncology
- Nanobody—A versatile tool for cancer diagnosis and therapeutics
- (2021) Manman Liu et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy
- (2021) Sandeep Surendra Panikar et al. JOURNAL OF CONTROLLED RELEASE
- Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells
- (2021) Daisuke Okajima et al. MOLECULAR CANCER THERAPEUTICS
- Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma
- (2021) Ramona Erber et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Smart transformable nanoparticles for enhanced tumor theranostics
- (2021) Jinjin Chen et al. Applied Physics Reviews
- Calcium ion nanomodulators for mitochondria-targeted multimodal cancer therapy
- (2021) Pan Zheng et al. Asian Journal of Pharmaceutical Sciences
- Targeting apoptosis in cancer therapy
- (2020) Benedito A. Carneiro et al. Nature Reviews Clinical Oncology
- A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
- (2018) Gentry T. King et al. INVESTIGATIONAL NEW DRUGS
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
- (2017) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
- (2016) P. Strop et al. MOLECULAR CANCER THERAPEUTICS
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
- (2015) R. M. Sharkey et al. CLINICAL CANCER RESEARCH
- Trop-2 Is a Determinant of Breast Cancer Survival
- (2014) Federico Ambrogi et al. PLoS One
- Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway
- (2013) Ting Liu et al. PLoS One
- Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain
- (2013) Tilen Vidmar et al. PROTEIN EXPRESSION AND PURIFICATION
- The Trop-2 signalling network in cancer growth
- (2012) E Guerra et al. ONCOGENE
- Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
- (2010) Rafael Cubas et al. Molecular Cancer
- High expression of TROP2 correlates with poor prognosis in pancreatic cancer
- (2008) D Fong et al. BRITISH JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now